 |
| 서울 송파구 방이동 한미약품 본사 (사진 = 연합뉴스) |
[Alpha Biz=(Chicago) Reporter Paul Lee] Hanmi Pharmaceutical posted positive results in the first quarter of this year.
It surpassed KRW 100 billion for the first time in quarterly sales and is the largest quarterly performance ever, except when short-term profits surged in 2015 due to the performance of new drug licenses.
Hanmi Pharmaceutical said in a public announcement on the 26th that it has achieved sales of 361.7 billion won, operating profit of 60.5 billion won and net profit of 49.6 billion won in the first quarter of this year. Compared to the same period last year, sales grew 12.6%, operating profit grew 47.9% and net profit grew 98.1%, and R&D invested 45.7 billion won, or 12.6% of its sales.
Based on competitive improved and complex new drugs such as Rosuget and Amosaltan Family, Hanmi Pharm has achieved external prescription performance of 202 billion won (based on pharmaceutical market research firm UBST), up 4% year-on-year in the first quarter of this year alone. Since 2018, Hanmi Pharmaceutical has maintained the top spot in sales outside the country for five consecutive years.
In particular, the sustainable growth of Beijing Hanmi Pharmaceutical, a local subsidiary of Hanmi Group in China, greatly contributed to Hanmi Pharmaceutical's first-quarter positive performance. Beijing Hanmi Pharmaceutical surpassed 100 billion won in quarterly sales for the first time since its establishment, realizing 111 billion won in first-quarter sales, with operating profit and net profit of 30.8 billion won and 27.9 billion won, respectively. Sales grew 17.1% year-on-year, while operating profit and net profit grew 21.1% and 21.9%, respectively.
The main product of Beijing Hanmi Pharmaceutical, the children's suit "Mami I," increased 31.6% year-on-year, while the constipation medicine "Ridong" and cough sputum medicine "Ianping" increased 40% and 174.8%, respectively.
Meanwhile, Hanmi Science, the holding company of Hanmi Group, posted sales of 291.3 billion won, operating profit of 31.3 billion won and net profit of 27.1 billion won in the first quarter.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
